News Releases

The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

A molecule produced in the liver in response to low-carb “ketogenic” diets has a powerful effect in suppressing colorectal tumor growth and may be useful as a preventive and treatment of such cancers, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

A generous $10 million gift from the Abramson Family Foundation will help ensure Penn Medicine’s Abramson Cancer Center remains on the leading edge of cancer research and care.

Robert H. Vonderheide, MD, DPhil, has been appointed to a second five-year term as director of the Abramson Cancer Center (ACC) at the University of Pennsylvania, following a highly successful tenure.

"CDH17CAR T cells can eliminate solid tumors like NETs and GICs, but do not damage healthy, normal tissues that also express CDH17, because CDH17 is sequestered and hidden between the normal cells,” said senior author Xianxin Hua, MD, PhD.

The Department of Radiation Oncology will use the $12.3 million, five-year NIH grant to compare the ability of proton, carbon and electron radiotherapy to protect normal tissues from harmful effects while controlling or eradicating solid tumors of the gastrointestinal tract, lungs, soft tissues throughout the body, and bones.

“This long-term remission is remarkable, and witnessing patients living cancer-free is a testament to the tremendous potency of this 'living drug' that works effectively against cancer cells,” said J. Joseph Melenhorst, PhD

Preliminary findings from an ongoing first-in-human clinical trial examining the safety and feasibility of chimeric antigen receptor macrophage (CAR-M) has helped to establish the viability of this innovative immunotherapy for solid cancer tumors.

Penn Medicine has been awarded a prestigious seven-year, $14 million grant from the National Institutes of Health (NIH) to promote organ transplantation for patients with end-stage renal disease who are currently on the waitlist for a kidney transplant.